Browsing: Artelo Biosciences has completed enrollment of the first three cohorts in the CAReS study assessing ART 27.13 for the treatment of cancer-related anorexia and weight loss.

Weight Loss

Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

By adminJuly 19, 20220

Solana Beach, CA, July 19, 2022 (GLOBE NEWSWIRE)-Artelo Biosciences, Inc. (Nasdaq: ARTL), A clinical-stage pharmaceutical company focused on regulating lipid…